CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer.
Ogimoto T, Ozasa H, Yoshida H, Nomizo T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Yamazoe M, Ajimizu H, Tsuji T, Sakamori Y, Kuninaga K, Morita S, Hirai T.
Ogimoto T, et al. Among authors: kuninaga k.
Oncol Lett. 2023 Jul 10;26(2):364. doi: 10.3892/ol.2023.13950. eCollection 2023 Aug.
Oncol Lett. 2023.
PMID: 37545625
Free PMC article.